Susquehanna International Group’s PharmaCyte Biotech PMCB Stock Holding History

Susquehanna International Group’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-39,900	Closed	-$116K	–	12890
2023 Q1	$116K	Buy	39,900 +3,000	+8%	+$8.82K	﹤0.01%	11164
2022 Q4	$108K	Sell	36,900 -35,900	-49%	-$103K	﹤0.01%	10899
2022 Q3	$175K	Sell	72,800 -80,400	-52%	-$203K	﹤0.01%	11030
2022 Q2	$346K	Buy	+153,200	New	+$335K	﹤0.01%	9188
2022 Q1	–	Sell	-28,500	Closed	-$71K	–	13750
2021 Q4	$71K	Buy	+28,500	New	+$78.5K	﹤0.01%	12368

Other funds holding PMCB

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Susquehanna International Group's PMCB Position: Q3 2025 in Review

Susquehanna International Group sold out of PharmaCyte Biotech (PMCB) in Q3 2025, closing a stake of 27,606 shares — an estimated $30.4K sold.

Susquehanna International Group first reported a position in PMCB in Q1 2022 and held it in 11 quarters. The position peaked at $311K in Q1 2023. 23 funds tracked by Wall St. Rank hold PMCB as of Q3 2025.

Susquehanna International Group reported no remaining PharmaCyte Biotech position as of Q3 2025 after selling out during the quarter.
Susquehanna International Group sold 27,606 PharmaCyte Biotech shares in Q3 2025, an estimated $30.4K.
Susquehanna International Group first reported a position in PharmaCyte Biotech in Q1 2022 and held it in 11 quarters.
Susquehanna International Group's PharmaCyte Biotech position peaked at $311K in Q1 2023.
23 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q3 2025.

Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.